Navigation Links
Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
Date:6/10/2008

on to HGS1029 (AEG40826), Aegera has three other programs in clinical development:

- AEG35156 targets the key anti-apoptotic protein XIAP, and is currently

in multiple Phase II human clinical trials for the treatment of solid

tumors and leukemia;

- AEG41174 is a novel, non-ATP competitive, small molecule tyrosine

kinase inhibitor targeting therapeutically significant kinases

including JAK2 and Bcr-Abl, and is currently in Phase I clinical

studies;

- AEG33773 is a novel, orally bioavailable small molecule developed to

treat painful diabetic neuropathy and is in Phase I clinical studies.

Website: http://www.aegera.com


'/>"/>
SOURCE AEGERA THERAPEUTICS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Aegera Therapeutics welcomes two experienced executives to its board of directors
2. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
3. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
4. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Arana Therapeutics Ltd.
5. Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program
6. Loic Maurel Joins Exonhit Therapeutics to Become CEO
7. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
8. CV Therapeutics Announces Presentations at the American Diabetes Association 68th Scientific Sessions
9. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
10. Takedas Antibody Therapeutics Research Company, Takeda San Francisco, Inc. Appoints Mary Haak-Frendscho, Ph.D. as President and CSO
11. Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... ... July 02, 2015 , ... Sleepless nights will become obsolete as Luzi ... its Indiegogo campaign on June 23. Sound sleepers and the sleep deprived both will ... to use, while the integration of the Bluetooth speaker, alarm clock and ability to ...
(Date:7/1/2015)... and PARIS , ... AgBiome, and Genective, key developer of biotech crops, ... discovery of new generations of insect control traits. ... control to counter the realities of advancing insect ... aligning AgBiome,s unique insect control technology with Genective,s ...
(Date:7/1/2015)... AURORA, Colo. and BANGALORE, India ... a global genomic profiling company that uses next generation ... appointment of Scott A. Storrer as chief ... and CEO, he will be responsible for all strategy, ... Vijay Chandru , who has served as Strand,s chairman ...
(Date:7/1/2015)... Isagenix International, a leading global health and ... Silver, and three Bronze Stevie® Awards at the 2015 ... Chicago this month.The American Business Awards ... in the U.S. "Winning is a ... leaders, cultivating talent, creating a unified team, and crafting ...
Breaking Biology Technology:Luzi Smart Lamp Recently Launched Indiegogo Campaign 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 3AgBiome and Genective collaborate to create novel insect-resistant crops 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Isagenix Earns Nine American Business Awards 2Isagenix Earns Nine American Business Awards 3
... 28, 2011 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ... extension study (MOR-100) in which patients have continued treatment on ... the initial Phase 1/2 study of GALNS (MOR-002) were continued ... MOR-100 study, patients were treated at a 2.0 mg/kg/week dose ...
... AllograftPossibilities.org has rapidly grown into the premier ... on the web. Although it has the same life-saving ... still lesser understood by the general public. The nonprofit ... of bone and soft-tissue allografts for use in surgical ...
... SAN DIEGO, July 28, 2011 Verenium Corporation (NASDAQ: ... and commercialization of high-performance industrial enzyme solutions, today announced ... of its 5.5% Notes and approximately $3 million in ... are very pleased to have taken another important step ...
Cached Biology Technology:BioMarin Provides Update on GALNS Phase 1/2 Extension Study (MOR-100) 2BioMarin Provides Update on GALNS Phase 1/2 Extension Study (MOR-100) 3BioMarin Provides Update on GALNS Phase 1/2 Extension Study (MOR-100) 4BioMarin Provides Update on GALNS Phase 1/2 Extension Study (MOR-100) 5BioMarin Provides Update on GALNS Phase 1/2 Extension Study (MOR-100) 6AllograftPossibilities.org Meets Unmet Need for Consumer-Oriented Information on Tissue Donation, Transplantation on the Internet 2AllograftPossibilities.org Meets Unmet Need for Consumer-Oriented Information on Tissue Donation, Transplantation on the Internet 3Verenium Announces Debt Repurchase 2Verenium Announces Debt Repurchase 3
(Date:6/23/2015)... Fla. , June 23, 2015 /PRNewswire/ ... management and authentication solutions, today announced enhanced functionality ... multi-factor authentication solution.  The enhancements build on ... of the DigitalPersona Altus platform and provide ... compatibility. In today,s environment of ...
(Date:6/17/2015)... , June 17, 2015 QIAGEN ... launched new Investigator ® STR assay kits for analysis ... United States . The new genetic fingerprint kits provide ... (short tandem repeats or STRs) for DNA matching. They incorporate ... of DNA in each sample, a novel QIAGEN technology that ...
(Date:6/16/2015)... 16, 2015  With the increasing number and severity ... top concern. The recent compromise of Federal employee ... strong authentication within government agencies. HYPR Corp. ... password (OTP) authenticator, has been submitted for testing and ... 3 validation for tamper proofing. The ...
Breaking Biology News(10 mins):Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3
... (CHICAGO - Sept. 30, 2009) U.S. Environmental Protection Agency,s ... of a dioxin exposure study conducted by the University ... the study was conducted well and provided useful, scientifically ... to help EPA fully evaluate human exposure to levels ...
... KINSTON, N.C., Oct. 1 Spatial Integrated Systems, ... integration of solutions incorporating next-generation digital 3D data ... United States patent application has been published for ... 3-dimensional image rendering" under Publication No. US2009/0169095A1. , ...
... University of Warwick and Rothamsted Research have been awarded ... (BBSRC) in partnership with Syngenta, to research the decline ... have fallen by 10-15% over the last 2 years; ... 30% for 2008. Since the declines were first reported ...
Cached Biology News:EPA reviews Univ. of Michigan dioxin study 2Spatial Integrated Systems, Inc. Files Patent Application 2£1 million award to address honeybee decline 2£1 million award to address honeybee decline 3